期刊文献+

急性ST段抬高心肌梗死临床特点及院内再灌注方式对远期死亡的影响 被引量:3

Impact of the clinical features of acute ST-elevation myocardial infarction and in-hospital reperfusion mode on longterm mortality
下载PDF
导出
摘要 目的:探讨急性ST段抬高心肌梗死(ST-elevation myocardial infarction,STEMI)的临床特点及院内再灌注方式对远期死亡的影响。方法连续收集我院急救中心2008年1月~2011年12月院前急救的急性STEMI患者80例临床资料,对其19项临床特点和院内再灌注方式(包括溶栓和/或PCI治疗)进行回顾性分析,探讨影响其病死率的危险因素。结果平均随访(42.3±12.3)个月,总病死率为22.5%(18/80),合并心源性休克患者病死率为61.5%(8/13),转诊至有能力行PCI医院者病死率为18.0%(11/61),首次医疗接触至有能力行 PCI 医院的时间为(31.9±14.7)min,转诊至无能力行 PCI医院者病死率为36.8%(7/19)。接受再灌注治疗患者的病死率明显低于未再灌注治疗者(P〈0.001),不同再灌注方式及转诊去向对病死率无显著影响。心源性休克(P〈0.05,RR 8.561,95%CI 1.325~55.324)、未再灌注治疗(P〈0.001,RR 20.860,95%CI 4.431~162.811)是急性STEMI患者死亡的独立预测因素。结论心源性休克、未再灌注治疗是急性STEMI患者死亡的独立预测因素,院前急救STEMI最重要的是尽快行再灌注治疗,降低其病死率。 Objective To investigate the effects of clinical features of acute ST-elevation myocardial infarction and in-hospital reperfusion mode on long-term mortality. Methods Retrospective analysis was performed on eighty consecutive pa-tients with acute ST-elevation myocardial infarction in our hospital from Jan 2008 to Dec 2011. Univariate and multivariate anal-ysis were carried out to assess the predictive value of 19 clinical variables and in-hospital reperfusion mode (including thrombol-ysis and/or PCI). Explored the factors impacting mortality. Results The mean follow-up was (42.3±12.3) months. The overall mortality was 22.5%(18/80). In patients with cardiogenic shock, the mortality was 61.5%(8/13). The mortality of patients ad-mitted at PCI-capable hospital was 18.0%(11/61), first medical contact (FMC) to device time was (31.9±14.7) minutes,and the mortality of patients who admitted at PCI-incapable hospital was 36.8%(7/19). The mortality rate was significantly lower in patients undergoing reperfusion therapy than the patients without reperfusion therapy (P〈0.001). Different reperfusion modes and transportation destination had no significant influence on mortality. By multivariate analysis, cardiogenic shock(P〈0.05, RR 8.561, 95%CI 1.325~55.324) and no reperfusion therapy (P〈0.001, RR 20.860, 95%CI 4.431~162.811) were independent predictors of death in acute STEMI patients. Conclusion In acute STEMI patients, cardiogenic shock and no reperfusion therapy are in-dependent predictors of mortality. For acute STEMI patients, the most important thing is to perform reperfusion therapy as soon as possible to decrease mortality.
出处 《中国现代医药杂志》 2014年第7期57-60,共4页 Modern Medicine Journal of China
关键词 急性ST段抬高心肌梗死 心源性休克 再灌注方式 病死率 Acute ST-elevation myocardial infarction Cardiogenic shock Reperfusion mode Mortality
  • 相关文献

参考文献9

  • 1刘尧,杨艳敏,朱俊,谭慧琼,梁岩,刘力生,丽英.急性心肌梗死合并心原性休克死亡危险因素分析[J].中华心血管病杂志,2010,38(8):695-701. 被引量:13
  • 2Marcolino MS,Simsek C,de Boer SP,et al. Short and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute infarction complicat-ed by cardiogenic shock[J]. Cardiology, 2012,121 ( 1 ) :47-55.
  • 3Zeymer U ,Vogt A ,Zahn R,et 8.1. Predictors of in-hospital mortal- ity in 1333 patients with acute myocardial infarction complicated by cardiogenie shock treated with primary percutaneous coronary intervention (PCI) [J]. European Heart Journal, 2004,25 (4) : 322- 328.
  • 4李惟铭,王乐丰,杨新春,等.急性心肌梗死并发心源性休克患者急诊经皮冠状动脉介入时间早晚对预后的影响[J].中华心血管病杂志,2005,33(3):60-64.
  • 52013 ACC/AHA guideline for the management of ST-elevation myocardial infarction:executive summary:a report of the Ameri- can College of Cardiology Foundation/Ameiean Haert Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,61 (4) :485-510.
  • 6中国急性冠脉综合征多中心临床研究协作组.211例急性ST段抬高心肌梗死不同治疗方法临床结果分析[J].中华心血管病杂志,2002,30(12):724-727. 被引量:37
  • 7郭丽君 何立芸 高炜.急性心肌梗死院内死亡患者临床特征分析.中华心血管病杂志,2005,33(1):42-45.
  • 8Kirchberger I,Heier M, Kuch B,et al. Presenting symptoms of my- ocardial infarction predict short and long-term mortality[J]. Amer- ican Heart Journal, 2012,164 (6) : 856-861.
  • 9宋莉,颜红兵,杨进刚,孙艺红,李超,胡大一.北京市急性ST段抬高心肌梗死患者转诊现况调查[J].中华心血管病杂志,2010,38(5):406-410. 被引量:17

二级参考文献31

  • 1Kushner FG,Hand M,Smith SC Jr,et al.2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guidelineand 2007 focused update) a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2009,54:2205-2241.
  • 2Van de Werf F,Bax J,Betriu A,et al.Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation:the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology.Eur Heart J,2008,29:2909-2945.
  • 3Widimsk(y) P,Budeslnslcy T,Vortc D,et al.Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction.Final results of the randomized national multicentre trial:PRAGUE-2.Eur Heart J,2003,24:94-104.
  • 4Andersen HR,Nielsen TT,Rasmussen K,et al.A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.N Engl J Med,2003,349:733-742.
  • 5Bonnefoy E,Lapostolle F,Leizorovicz A,et al.Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction:a randomised study.Lancet,2002,360:825-829.
  • 6Dalby M,Bouzamondo A,Lechat P,et al.Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction:a meta-analysis.Circulation,2003,108:1809-1814.
  • 7Grines CL,Westerhausen DR Jr,Grines LL,et al.A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction:the air primary angioplasty in myocardial infarction study.J Am Coll Cardiol,2002,39:1713-1719.
  • 8Widimsky P,Bilkova D,Penicka M,et al.Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention.Five years' follow-up of the PRAGUE-2 trial.Eur Heart J,2007,28:679-684.
  • 9Westfall JM,Kiefe CI,Weissman NW,et al.Does interhospital transfer improve outcome of acute myocardial infarction? A propensity score analysis from the cardiovascular cooperative project.BMC Cardiovasc Disord,2008,8:22.
  • 10Cannon CP,Gibson CM,Lambrew CT,et al.Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.JAMA,2000,283:2941-2947.

共引文献62

同被引文献35

  • 1No authors Iisted. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The Miami Trial Research Group [ J ]. Eur Heart J, 1985,6 ( 3 ) : 199-226.
  • 2ISIS-1 collaborate group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1 [ J ]. Lan- cet, 1986,2 ( 8498 ) : 57-66.
  • 3American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O "gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ]. J Am Call Cardiol,2013,61 (4) :e78-140.
  • 4Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred be- ta-blockade following thrombolytic therapy in patients with acute myo- cardial infarction. Results of the Thrombolysis in Myocardial Infarction ( TIMI ) II-B Study [ J ]. Cilculation, 1991,83 ( 2 ) :422 -437.
  • 5Pfisterer M, Cox JL, Granger CB,et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experi- ence. Global Utilization of Streptokinase and TPA (alteplase) for Occlu- ded Coronary Arteries[J]. J Am Coil Cardiol,1998,32(3) :634-640.
  • 6Harjai K J, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocar- dial infarction[J]. Am J Cardiol,2003,91 (6) :655"660.
  • 7Halkin A, Gfines CL, Cox DA, et al. Impact of intravenous beta-block- ade before primary angioplasty on survival in patients undergoing me- chanical reperfusion therapy for acute myocardial infarction [ J ]. J Am Coil Cardio1,2004,43 (10) : 1780-1787.
  • 8Valle JA, Zhang M, Dixon S, et al. Impact of pre-proeedural beta block- ade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction [ J ]. Am J Cardio1,2013 ,111 ( 12 ) : 171;4-1720.
  • 9Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the effi- cacy and safety of landiolol, an ultra-short-acting 131-adrenergic bloc- ker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [ J ]. Circ J,2012,76 ( 2 ) :439-445.
  • 10Van De Weft F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy[ J]. J Am Coil Cardiol, 1993,22 (2) :407-416.

引证文献3

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部